All In Biotech

Drug Trial Radar · NCT04146285

A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

A Phase I Clinical Trial of BAT4406F Injection on the Safety, Tolerability, and Pharmacokinetics in Patients With Neuromyelitis Optica Spectrum Disorders

Last checked: Nov 19, 2026Latest source record: Jul 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

Sep 1, 2020

Primary completion

Mar 13, 2023

Study completion Dec 25, 2023

Sponsor

Lead sponsor
Bio-Thera SolutionsIndustry
Sponsor type
Industry
First posted
Oct 31, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase I clinical study of the safety, tolerability, and pharmacokinetics of BAT4406F injection in patients with neuromyelitis optica spectrum disorders.

Conditions

  • Neuromyelitis Optica Spectrum Disorders

Interventions

  • BAT4406FDrug

    Open-label dose escalation starting from 20mg. Route of administration: intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity(DLT)Time frame: 4weeks
  2. Maximum tolerated dosed (MTD)Time frame: up to 6 months
  3. Area under the curve (AUC)Time frame: up to 6 months
  4. Maximum serum drug concentration (Cmax)Time frame: up to 6 months
  5. Half-life period(t1/2)Time frame: up to 6 months
  6. Maximum serum drug time (Tmax)Time frame: up to 6 months
  7. CD19+ B lymphocyte ratioTime frame: up to 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital affiliated to Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.